WO2005009374A8 - Ceramide dependent-stabilization of bace1 - Google Patents

Ceramide dependent-stabilization of bace1

Info

Publication number
WO2005009374A8
WO2005009374A8 PCT/US2004/023476 US2004023476W WO2005009374A8 WO 2005009374 A8 WO2005009374 A8 WO 2005009374A8 US 2004023476 W US2004023476 W US 2004023476W WO 2005009374 A8 WO2005009374 A8 WO 2005009374A8
Authority
WO
WIPO (PCT)
Prior art keywords
ceramide
bace1
stabilization
dependent
diagnosing
Prior art date
Application number
PCT/US2004/023476
Other languages
French (fr)
Other versions
WO2005009374A3 (en
WO2005009374A2 (en
Inventor
Luigi Puglielli
Dora M Kovacs
Original Assignee
Gen Hospital Corp
Luigi Puglielli
Dora M Kovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Luigi Puglielli, Dora M Kovacs filed Critical Gen Hospital Corp
Publication of WO2005009374A2 publication Critical patent/WO2005009374A2/en
Publication of WO2005009374A8 publication Critical patent/WO2005009374A8/en
Publication of WO2005009374A3 publication Critical patent/WO2005009374A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to methods and products for inhibiting ceramide associated Aβ accumulation. The invention is useful for screening compounds for such activity, as well as diagnosing, preventing, and treating Alzheimer’s disease and other disorders associated with β-secretase processing of substrates.
PCT/US2004/023476 2003-07-21 2004-07-21 Ceramide dependent-stabilization of bace1 WO2005009374A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48995503P 2003-07-21 2003-07-21
US60/489,955 2003-07-21

Publications (3)

Publication Number Publication Date
WO2005009374A2 WO2005009374A2 (en) 2005-02-03
WO2005009374A8 true WO2005009374A8 (en) 2005-05-26
WO2005009374A3 WO2005009374A3 (en) 2005-10-27

Family

ID=34102952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/023476 WO2005009374A2 (en) 2003-07-21 2004-07-21 Ceramide dependent-stabilization of bace1

Country Status (1)

Country Link
WO (1) WO2005009374A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US20100080807A1 (en) * 2008-09-26 2010-04-01 National Taiwan University Methods and Compositions for Treating Viral Hemorrhagic Fever
US20190358184A1 (en) * 2016-12-13 2019-11-28 Ecole Polytechnique Federale De Lausanne Methods of treating amyloid-beta peptide diseases

Also Published As

Publication number Publication date
WO2005009374A3 (en) 2005-10-27
WO2005009374A2 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
IL188330A (en) Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione compounds
WO2006121560A8 (en) Methods and compositions for treatment of cns disorders
WO2008011476A3 (en) Compositions and methods for modulating sirtuin activity
WO2006083533A3 (en) Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
EP2977452A3 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders
SI1511710T1 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer s disease, type 2 diabetes, and parkinson s disease
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
WO2000038618A3 (en) SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
WO2004080376A3 (en) Hydroxyethylamine compounds having asp2 inhibitory activity for the treatment of alzheimer’s disease
DE602006016449D1 (en)
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
WO2005087751A3 (en) Substituted hydroxyethylamine aspartyl protease inhibitors
MX2008002166A (en) Compounds and compositions as tpo mimetics.
WO2005087752A8 (en) Substituted hydroxyethylamine aspartyl protease inhibitors
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2006042137A3 (en) Methods for identifying parkinson's disease therapeutics
WO2005110468A3 (en) Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia
WO2006058720A3 (en) Novel compounds for the treatment of neurological disorders
WO2006089286A3 (en) Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor compounds useful for the treatment and prevention of pain and screening methods therefor
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2005117941A3 (en) Methods and compositions for the treatment of polycystic diseases
CA2534643A1 (en) Methods for screening and identifying compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 05/2005 UNDER (72, 75) THE ADDRESS OF "PUGLIELLI, LUIGI" SHOULD READ "UNIVERSITY OFWISCONSIN MEDICAL SCHOOL, VETERAN S ADMINISTRATIONHOSPITAL (GREEC 11G), 2500OVERLOOK TERRACE, MADISON, WI 53705 (US) "

122 Ep: pct application non-entry in european phase